Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction

Bioorg Med Chem Lett. 2004 Mar 22;14(6):1577-80. doi: 10.1016/j.bmcl.2003.12.090.

Abstract

In a continuing effort to discover novel chemotypes as potent and selective PDE5 inhibitors for the treatment of male erectile dysfunction (ED), we have found that 4-benzylaminoquinoline derivatives are very potent and selective PDE5 inhibitors. Some compounds in this series had PDE5 IC(50)'s as low as 50 pM. While an electron withdrawing group at the C6-position of the quinoline substantially improved PDE5 potency, an ethyl group at the C8-position not only improved the PDE5 potency but also the isozyme selectivity. Substitutents at the C3-position can incorporate a variety of different groups. The synthesis and primary structure-activity relationship of this new series of potent PDE5 inhibitors are described.

MeSH terms

  • 3',5'-Cyclic-GMP Phosphodiesterases / antagonists & inhibitors*
  • 3',5'-Cyclic-GMP Phosphodiesterases / metabolism
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • Erectile Dysfunction / drug therapy*
  • Erectile Dysfunction / enzymology
  • Humans
  • Male
  • Phosphodiesterase Inhibitors / chemistry
  • Phosphodiesterase Inhibitors / pharmacology*
  • Phosphodiesterase Inhibitors / therapeutic use
  • Quinolines / chemistry
  • Quinolines / pharmacology*
  • Quinolines / therapeutic use

Substances

  • Phosphodiesterase Inhibitors
  • Quinolines
  • 3',5'-Cyclic-GMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • PDE5A protein, human